How Are Life Science MNCs Leveraging Indian GCCs for R&D?

The life science industry is growing at a rapid pace due to a confluence of investment, innovation, and global health priorities. Top companies in this sector are Pfizer and AbbVie who continue to grow in terms of lead generation. Further, life science is also at the forefront of a digital renaissance embracing data-driven R&D as an imperative. It is more like a bedrock of competitive advantage in a highly regulated environment. Owing to this, the life science analytics market size is expected to grow from $13.78 billion in 2025 to $$27.75 billion in 2032. The market includes vast volumes of data from pharmaceuticals, biotechnology, and diagnostics sectors along with sub-sectors like gene therapy and biotech.

Harnessing and navigating such a data-rich and insight-hungry landscape is not a cake walk. It demands a deep fusion of digital fluency, knowledge of real-time clinical data like predictive patient insights, and scalable execution. Enter global capability centers in India, the ultimate innovation engines causing a paradigm shift in global business strategy. They are helping life science organizations reimagine R&D – from molecule to the market. GCCs in India are embedding data science in the heart of discovery ushering a new era of intelligent and outcome-driven research.

Read to see what GCCs are doing in this field.

Indian GCC: Empowering Life Science Innovation

The below points encapsulate how GCCs in India act as strategic enablers for life sciences firms driving exceptional data-driven research innovation and growth.

https://inductusgcc.com/wp-content/uploads/2025/04/RD-in-life-Image.jpg

Data Analytics Capabilities: The role of Indian GCCs in pharma innovation includes harnessing cutting-edge AI, machine learning, and big data analytics to streamline R&D processes. This is done by identifying and analyzing vast datasets to uncover insights, predict outcome, and accelerate innovation.
Digital-First Clinical Trials: Life sciences global capability centers help with hybrid and decentralized clinical trials by building digital platforms, real-time data capture solutions, and remote monitoring tools that improves both speed and patient engagement.
Personalized Medicine: GCCs in India are proactively using patient data analytics, genomics, and artificial intelligence to improve treatment outcomes, develop targeted therapies, and shift towards precision healthcare.
Regulatory Intelligence: Indian GCCs help life science farms track evolving requirements, automate regulatory submissions, support compliance, and promise faster audit-ready documents to avoid legal repercussions on parent companies.
Supply Chain Resistance: The proactive use of digital twin, predictive analytics, and IoT helps GCCs optimize pharmaceutical manufacturing processes. This ensures efficient and resilient supply chains to stay ahead of competitors.
Embedding Technology: The adoption of AI/ML, cloud platforms, and automation across clinical, regulatory, and R&D operations are being spearheaded by global capability centers in India to deliver efficiency and cost gains.

By maximizing machine learning, AI, ML, and Big Data, GCCs are ensuring life sciences digital transformation to analyze vast datasets and drive data-backed innovation.

https://inductusgcc.com/wp-content/uploads/2025/04/DeepSeek-Cost-Suggested-Read.jpg

Growing Number of Life Science GCCs in India

Prominent multinational biotechnology and pharmaceutical companies have a strong presence in India with their global capability centers. This includes Abbott, Pfizer, and Novartis. Firms like GSK, Mylan, and Amgen are also leveraging India’s strong tech talent pool to accelerate their clinical trials. Siemens Healthineers has particularly used its India GCC to accelerate digital transformation with healthcare technology.

Eli Lilly, a Fortune 500 Company already has its GCC in Bengaluru and is expanding in Hyderabad. Novo Nordisk, especially, has been integrating AI in personalized diabetes treatment and drug discovery in its Indian GCC in life sciences. Altogether, these are bright examples and inspirations for life science organizations who are still in two minds regarding setting up a GCC here in India.

The Future of Life Science GCCs: The Road Ahead

India’s life science and healthcare GCC sector is set for rapid expansion to reach a $100 billion valuation by 2030 with 2,500 centers and 4.5 million experts employed by 2025. Given the rapid pace, it is imperative that global pharmaceuticals and healthcare leaders will rely on India even in future for commercial operations including clinical trials and drug discovery.

Key factors that are likely to surge this growth are next-gen technological frameworks, startup collaborations, and tier-II city expansions. Therefore, as life science continues its evolution into a precision-led and data-driven industry, the role of GCCs will become even more pivotal. The world will see how pharma uses GCC in India to architect the future of discovery, research, and patient-centric healthcare. In coming years, those companies that harness the full potential of these centers will move beyond just incremental steps to achieve radical breakthroughs in setting standards for a transformative impact.

Conclusion

The smartest way to ensure your global capability center is operating in the right direction is to partner with India’s leading GCC consulting firm. We offer COPO Model which ensures 60% lower operational costs, has pre-built systems, reduced Capex, and 90-days readiness along with complete control of IP. Further, firms can also explore COPO-Digital Twin Integrated Service Model which offers a mirror-like service model for seamless productivity.

https://inductusgcc.com/wp-content/uploads/2025/04/Get-GCC-advisory-CTA.jpg

The future of life sciences is being shaped at the intersection of technology, data, and deep-domain expertise and Indian GCCs are right at the forefront of the same. As boundaries between biological and digital sciences blur, organizations that invest early in GCC-led innovation stand the chance to lead not just markets but industries.